Information  X 
Enter a valid email address

Cambridge Antibody (CAT)

  Print      Mail a friend

Friday 03 March, 2006

Cambridge Antibody

Holding(s) in Company

Cambridge Antibody Tech Group PLC
03 March 2006

                   NOTIFICATION OF MAJOR INTERESTS IN SHARES



1. Name of company



Cambridge Antibody Technology Group plc



2. Name of shareholder having a major interest



OrbiMed



3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18



As in 2. above



4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them



Not known



5. Number of shares / amount of stock acquired



N/A



6. Percentage of issued class



N/A



7. Number of shares / amount of stock disposed



Not known



8. Percentage of issued class



Not Known



9. Class of security



Ordinary 10 pence Shares



10. Date of transaction



Not known



11. Date company informed



3 March 2006



12. Total holding following this notification



Not known



13. Total percentage holding of issued class following this notification



Not known



14. Any additional information



The Company has been advised that Orbimed Advisors LLC and OrbiMed Capital LLC
(collectively "Orbimed" ), through various entities over which it has
investment discretion, no longer has any interest in ordinary shares or ADR's of
the Company



15. Name of contact and telephone number for queries



Justin Hoskins, 01223 898589



16. Name and signature of authorised company official responsible for making
this notification



Justin Hoskins, Company Secretary



Date of notification



3 March 2006



The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.




                      This information is provided by RNS
            The company news service from the London Stock Exchange